Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Clin Psychopharmacol. 2018 Apr;38(2):144–148. doi: 10.1097/JCP.0000000000000837
Nagele: Dr. Nagele has filed for intellectual property protection related to the use of nitrous oxide in major depression. No other conflicts of interest related to this work. He has received research support from Roche Diagnostics, Abbot, and Express Scripts unrelated to this work.
Zorumski: Dr. Zorumski serves on the Scientific Advisory Board of Sage Therapeutics. Sage Therapeutics was not involved in this study.
Conway: Dr. Conway was previously on the speaker’s bureau for Bristol-Myers Squibb and Otsuka Pharmaceuticals. He has received research funding from Bristol-Myers Squibb, Cyberonics, the Stanley Baer Foundation and the Brain and Behavior Research Foundation